CD83 regulates lymphocyte maturation, activation and homeostasis

Trends in Immunology

Volumn 29, Issue 4, 2008, Pages 186-194

  Breloer, Minka ^a   Fleischer, Bernhard ^a  

^a BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD83 ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN STRUCTURE; B LYMPHOCYTE; BIOLOGICAL ACTIVITY; CD4+ T LYMPHOCYTE; CELL MATURATION; CELLULAR IMMUNITY; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSTIMULATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; THYMUS;

ANIMALS; ANTIGENS, CD; B-LYMPHOCYTES; CELL DIFFERENTIATION; DENDRITIC CELLS; HOMEOSTASIS; HUMANS; IMMUNOGLOBULINS; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; T-LYMPHOCYTE SUBSETS; UP-REGULATION;

EID: 41149094376     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2008.01.009     Document Type: Review

References (66)

1. Zhou L.J., and Tedder T.F. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J. Immunol. 154 (1995) 3821-3835
2. Berchtold S., et al. Cloning, recombinant expression and biochemical characterization of the murine CD83 molecule which is specifically upregulated during dendritic cell maturation. FEBS Lett. 461 (1999) 211-216
3. Lechmann M., et al. CD83 on dendritic cells: more than just a marker for maturation. Trends Immunol. 23 (2002) 273-275
4. Lechmann M., et al. Role of CD83 in the immunomodulation of dendritic cells. Int. Arch. Allergy Immunol. 129 (2002) 113-118
5. Prechtel A.T., and Steinkasserer A. CD83: an update on functions and prospects of the maturation marker of dendritic cells. Arch. Dermatol. Res. 299 (2007) 59-69
6. Zhou L.J., et al. A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the Ig superfamily. J. Immunol. 149 (1992) 735-742
7. Wolenski M., et al. Expression of CD83 in the murine immune system. Med. Microbiol. Immunol. 192 (2003) 189-192
8. Breloer M., et al. CD83 is a regulator of murine B cell function in vivo. Eur. J. Immunol. 37 (2007) 634-648
9. Kretschmer B., et al. CD83 modulates B Cell function in vitro: increased IL-10 and reduced Ig secretion by CD83Tg B cells. PLoS ONE 2 (2007) e755
10. Prazma C.M., et al. CD83 expression is a sensitive marker of activation required for B cell and CD4+ T cell longevity in vivo. J. Immunol. 179 (2007) 4550-4562
11. Cao W., et al. CD83 is preformed inside monocytes, macrophages and dendritic cells, but it is only stably expressed on activated dendritic cells. Biochem. J. 385 (2005) 85-93
12. Nicod L.P., et al. Upregulation of CD40, CD80, CD83 or CD86 on alveolar macrophages after lung transplantation. J. Heart Lung Transplant. 24 (2005) 1067-1075
13. Mailliard R.B., et al. IL-18-induced CD83+CCR7+ NK helper cells. J. Exp. Med. 202 (2005) 941-953
14. Yamashiro S., et al. Expression of CCR6 and CD83 by cytokine-activated human neutrophils. Blood 96 (2000) 3958-3963
15. Iking-Konert C., et al. Up-regulation of the dendritic cell marker CD83 on polymorphonuclear neutrophils (PMN): divergent expression in acute bacterial infections and chronic inflammatory disease. Clin. Exp. Immunol. 130 (2002) 501-508
16. Fujimoto Y., et al. CD83 expression influences CD4+ T cell development in the thymus. Cell 108 (2002) 755-767
17. Kozlow E.J., et al. Subtractive cDNA cloning of a novel member of the Ig gene superfamily expressed at high levels in activated B lymphocytes. Blood 81 (1993) 454-461
18. Twist C.J., et al. The mouse Cd83 gene: structure, domain organization, and chromosome localization. Immunogenetics 48 (1998) 383-393
19. Gavin M.A., et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445 (2007) 771-775
20. Fontenot J.D., et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22 (2005) 329-341
21. Prazma C.M., and Tedder T.F. Dendritic cell CD83: A therapeutic target or innocent bystander?. Immunol. Lett. 115 (2008) 1-8
22. Lechmann M., et al. CD83 is a dimer: Comparative analysis of monomeric and dimeric isoforms. Biochem. Biophys. Res. Commun. 329 (2005) 132-139
23. Hock B.D., et al. A soluble form of CD83 is released from activated dendritic cells and B lymphocytes, and is detectable in normal human sera. Int. Immunol. 13 (2001) 959-967
24. Senechal B., et al. Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83. Blood 103 (2004) 4207-4215
25. Kuwano Y., et al. CD83 influences cell-surface MHC class II expression on B cells and other antigen-presenting cells. Int. Immunol. 19 (2007) 977-992
26. McKinsey T.A., et al. Transcription factor NF-kappaB regulates inducible CD83 gene expression in activated T lymphocytes. Mol. Immunol. 37 (2000) 783-788
27. Berchtold S., et al. Cloning and characterization of the promoter region of the human CD83 gene. Immunobiology 205 (2002) 231-246
28. Klein E., et al. CD83 localization in a recycling compartment of immature human monocyte-derived dendritic cells. Int. Immunol. 17 (2005) 477-487
29. Lechmann M., et al. The extracellular domain of CD83 inhibits dendritic cell-mediated T cell stimulation and binds to a ligand on dendritic cells. J. Exp. Med. 194 (2001) 1813-1821
30. Scholler N., et al. CD83 is a sialic acid-binding Ig-like lectin (Siglec) adhesion receptor that binds monocytes and a subset of activated CD8+ T cells. J. Immunol. 166 (2001) 3865-3872
31. Hirano N., et al. Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. Blood 107 (2006) 1528-1536
32. Cramer S.O., et al. Activation-induced expression of murine CD83 on T cells and identification of a specific CD83 ligand on murine B cells. Int. Immunol. 12 (2000) 1347-1351
33. Garcia-Martinez L.F., et al. A novel mutation in CD83 results in the development of a unique population of CD4+ T cells. J. Immunol. 173 (2004) 2995-3001
34. Luthje K., et al. Transgenic expression of a CD83-immunoglobulin fusion protein impairs the development of immune-competent CD4-positive T cells. Eur. J. Immunol. 36 (2006) 2035-2045
35. Kruse M., et al. Inhibition of CD83 cell surface expression during dendritic cell maturation by interference with nuclear export of CD83 mRNA. J. Exp. Med. 191 (2000) 1581-1590
36. Zinser E., et al. Prevention and treatment of experimental autoimmune encephalomyelitis by soluble CD83. J. Exp. Med. 200 (2004) 345-351
37. Zinser E., et al. Determination of the inhibitory activity and biological half-live of soluble CD83: comparison of wild type and mutant isoforms. Immunobiology 211 (2006) 449-453
38. Hock B.D., et al. The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer 98 (2003) 1681-1688
39. Hock B.D., et al. Identification of a circulating soluble form of CD80: levels in patients with hematological malignancies. Leuk. Lymphoma 45 (2004) 2111-2118
40. Hock B.D., et al. The soluble form of CD83 is present at elevated levels in a number of hematological malignancies. Leuk. Res. 28 (2004) 237-241
41. Kruse M., et al. Mature dendritic cells infected with herpes simplex virus type 1 exhibit inhibited T-cell stimulatory capacity. J. Virol. 74 (2000) 7127-7136
42. Hock B.D., et al. Levels of the soluble forms of CD80, CD86, and CD83 are elevated in the synovial fluid of rheumatoid arthritis patients. Tissue Antigens 67 (2006) 57-60
43. Scholler N., et al. Cutting edge: CD83 regulates the development of cellular immunity. J. Immunol. 168 (2002) 2599-2602
44. Xu J.F., et al. A limited course of soluble CD83 delays acute cellular rejection of MHC-mismatched mouse skin allografts. Transpl. Int. 20 (2007) 266-276
45. Pashine A., et al. Failed efficacy of soluble human CD83-Ig in allogeneic mixed lymphocyte reactions and experimental autoimmune encephalomyelitis: Implications for a lack of therapeutic potential?. Immunol. Lett. 115 (2008) 9-15
46. Sharpe A.H., and Freeman G.J. The B7-CD28 superfamily. Nat. Rev. Immunol. 2 (2002) 116-126
47. Aerts-Toegaert C., et al. CD83 expression on dendritic cells and T cells: correlation with effective immune responses. Eur. J. Immunol. 37 (2007) 686-695
48. Prechtel A.T., et al. CD83 Knockdown in Monocyte-Derived Dendritic Cells by Small Interfering RNA Leads to a Diminished T Cell Stimulation. J. Immunol. 178 (2007) 5454-5464
49. Yang S., et al. Melanoma cells transfected to express CD83 induce antitumor immunity that can be increased by also engaging CD137. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 4990-4995
50. Wolenski M., et al. Enhanced activation of CD83-positive T cells. Scand. J. Immunol. 58 (2003) 306-311
51. Lechmann M., et al. Overexpression, purification, and biochemical characterization of the extracellular human CD83 domain and generation of monoclonal antibodies. Protein Expr. Purif. 24 (2002) 445-452
52. Zhou L.J., and Tedder T.F. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 2588-2592
53. Sorg U.R., et al. Hodgkin's cells express CD83, a dendritic cell lineage associated antigen. Pathology 29 (1997) 294-299
54. Dudziak D., et al. Latent membrane protein 1 of Epstein-Barr virus induces CD83 by the NF-kappaB signaling pathway. J. Virol. 77 (2003) 8290-8298
55. Koga T., et al. In situ localization of CD83-positive dendritic cells in psoriatic lesions. Dermatology 204 (2002) 100-103
56. te Velde A.A., et al. Increased expression of DC-SIGN+IL-12+IL-18+ and CD83+IL-12-IL-18- dendritic cell populations in the colonic mucosa of patients with Crohn's disease. Eur. J. Immunol. 33 (2003) 143-151
57. Plumb J., et al. CD83-positive dendritic cells are present in occasional perivascular cuffs in multiple sclerosis lesions. Mult. Scler. 9 (2003) 142-147
58. Iwamoto M., et al. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int. J. Cancer 104 (2003) 92-97
59. Furihata M., et al. Prognostic significance of CD83 positive, mature dendritic cells in the gallbladder carcinoma. Oncol. Rep. 14 (2005) 353-356
60. Tsukayama S., et al. Prognostic value of CD83-positive mature dendritic cells and their relation to vascular endothelial growth factor in advanced human gastric cancer. Oncol. Rep. 14 (2005) 369-375
61. Sieling P.A., et al. CD1 expression by dendritic cells in human leprosy lesions: correlation with effective host immunity. J. Immunol. 162 (1999) 1851-1858
62. Ohta Y., et al. Homologs of CD83 from elasmobranch and teleost fish. J. Immunol. 173 (2004) 4553-4560
63. Donate C., et al. CD83 expression in sea bream macrophages is a marker for the LPS-induced inflammatory response. Fish Shellfish Immunol. 23 (2007) 877-885
64. Hansell C., et al. Unique features and distribution of the chicken CD83+ cell. J. Immunol. 179 (2007) 5117-5125
65. Kotzor N., et al. The soluble form of CD83 dramatically changes the cytoskeleton of dendritic cells. Immunobiology 209 (2004) 129-140
66. Dudziak D., et al. Alternative splicing generates putative soluble CD83 proteins that inhibit T cell proliferation. J. Immunol. 174 (2005) 6672-6676